Both in Pharmaceuticals
Alto Neuroscience vs Aktis Oncology
Over the past year ANRO returned +39.9% and AKTS returned −24.9%; their daily moves had a correlation of 0.24.
ANRO +39.9% AKTS −24.9%Growth of $1, one year, split-adjusted
| Metric | ANRO | AKTS |
|---|---|---|
| Price | $22.91 | $16.82 |
| Market cap | $898.8M | $935.5M |
| Today | −1.23% | +2.25% |
| 1 month | −13.8% | −14.6% |
| 6 months | −5.7% | −10.1% |
| Year to date | +28.7% | — |
| 1 year | +87.0% | — |
| Revenue growth (YoY) | — | — |
| Gross margin | — | 100.0% |
| Net margin | — | −713.5% |
| P/E (TTM) | — | — |
| Price / sales | — | — |
| Net cash | $225.1M | $517.3M |
| Dividend yield | — | — |
| Volatility (60d) | 55.7% | 52.7% |
| Short % of float | 20.0% | 18.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).